 posit pipelin platform look
attract entri point downgrad
messag downgrad neutral buy remov pt
share increas vs btk past month without major
chang underli fundament remain posit platform pipelin
believ new investor might find better entri point sever potenti pipelin
updat could serv potenti catalyst guid vs
previous updat estim reflect financi result otherwis
consist investor expect
downgrad neutral context recent stock appreci guidanc
push two potenti near-term catalyst continu see potenti upsid
 engin bispecif antibodi platform pipelin well valu
out-licens royalti opportun ultomiri tafasitamab mor said
share price increas vs btk last month without
major posit chang fundament trade prior
pt furthermor two phase readout
push previous modestli delay two potenti near-term catalyst
inclus small cap index may driven addit
demand think current dilut market cap lot near-term
pipelin upsid price step sidelin
 may need exceed competitor benchmark
t-cell engag mosunetuzumab gener
addl upsid recal potenti competitor t-cell engag
read earli clinic data b-cell malign patient date includ
orr/cr rate r/r fl well cr rate
r/r dlbcl includ cr post car-t set report eha
mosunetuzumab orr/cr rate r/r fl orr/
cr rate r/r dlbcl
sum-of-the-part dcf impli per share valuat current model
po tafasitamab street consensu ultomiri sale expect launch
year po favor resolut
partial clinic hold link po find partner
obexelimab diseas system lupu in-hous bispecif
pipelin repres valuat po peak share assumpt
innov program cash repres balanc
updat estim account result finish
cash invest compani expect provid runway beyond
modestli increas incom ultomiri royalti forecast decreas tafasitamab
page analyst certif import disclosur
valuat risk
downgrad neutral remov pt previous
believ share fairli valu follow increas price vs btk
past month without chang fundament valu use
dcf-base valuat method use discount rate consist
clinic stage biotech compani coverag termin growth rate
appli downsid risk includ regulatori commerci
setback potenti emerg new competitor lower product sale expect
upsid risk includ pipelin commerci sale success beyond
includ forecast potenti acquisit premium current valuat
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
